ClinicalTrials.gg
TerminatedNCT01995058Updated Jan 8, 2026Results posted

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

A Phase 2 interventional study of cabozantinib and abiraterone in Prostate Cancer, Castration Resistant Prostate Cancer and Prostatic Neoplasms, sponsored by Exelixis. Terminated at 20 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Exelixis · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decided to close the study prior to completion of enrollment. This was a business decision and not based on the safety results of the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.

Enrollment
8th of 23
54 · median 33
Started
2014
with 1 other
Phase 2
12 of 23
1 open now
Registered
13th of 23
by date
Lead sponsor
6 of 23
Exelixis

Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 12 in phase 2, and was the 13th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cabozantinib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).

Read the detailed description

The goal of this clinical trial was to learn if the combination of the drugs cabozantinib and abiraterone works for men that were chemotherapy-naive, bone metastasis CRPC patients. It was designed to learn about the safety of cabozantinib. The main questions are:

  1. Does it work and is it safe in men with chemotherapy-naïve bone- metastatic castration resistant CRPC?
  2. What was the clinical benefit at different dose levels of the combination of abiraterone and cabozantinib in this patient population?

Participants were assigned to one of the four treatment groups:

Arm 1. cabozantinib at a dose of 40 mg every day (QD) plus abiraterone with prednisone; Arm 2. cabozantinib at a dose of 20 mg QD plus abiraterone with prednisone; Arm 3. cabozantinib at a dose of 20 mg every other day (QOD) plus abiraterone with prednisone; Arm 4. abiraterone with prednisone.

03

Conditions studied

  • Prostate Cancer
  • Castration Resistant Prostate Cancer
  • Prostatic Neoplasms

Browse trials for

Keywords

  • CRPC
  • castration resistant prostate cancer
  • prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate.
  • Must be surgically or medically castrated (serum testosterone levels less than or equal to 50 ng/dL)
  • Must have castration-resistant prostate cancer (CRPC) with disease progression during LHRH therapy or after a surgical bilateral orchiectomy.
  • Bone related to prostate cancer
  • Adequate organ and marrow function
  • Capable of understanding and complying with the protocol requirements and signed the document
  • Sexually active subjects and their partners must agree to use medically accepted methods of barrier (eg, male condom or female condom) as well as one other medically accepted method of contraception during the course of the study treatment and for 4 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Any prior treatment with abiraterone, enzalutamide, or any agents blocking androgen receptor (AR) or androgen synthesis.
  • Any prior treatment with cabozantinib or participation in a prior clinical trial of cabozantinib.
  • Any prior cytotoxic therapy (including estramustine) or biologic therapy for the treatment of prostate cancer (a few exceptions will be allowed)
  • Any prior radionuclide therapy (eg, samarium 153, strontium 89, alpharadin)
  • Use of investigational agent within 28 days
  • Any pathological finding consistent with small cell carcinoma of the prostate
  • Known or cranial epidural disease
  • Diagnosis of another within 2 years, except for superficial non-melanoma skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Arm 1: Cabozantinib 40 mg + abiraterone with prednisone

    Cabozantinib 40 mg, by mouth daily (po QD), + abiraterone with prednisone

    Drug: cabozantinib · Drug: abiraterone · Drug: prednisone

  • Experimental
    Arm 2: Cabozantinib 20 mg + abiraterone and prednisone

    Cabozantinib 20 mg, by mouth daily (po QD), + abiraterone with prednisone

    Drug: cabozantinib · Drug: abiraterone · Drug: prednisone

  • Experimental
    Arm 3: Cabozantinib 20 mg (every other day) + abiraterone and prednisone

    Cabozantinib 20 mg every other day with abiraterone and prednisone

    Drug: cabozantinib · Drug: abiraterone · Drug: prednisone

  • Active comparator
    Arm 4: Abiraterone and prednisone only

    Abiraterone with prednisone

    Drug: abiraterone · Drug: prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Radiographic Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause, as assessed by Independent Radiology Committee (IRC). The sponsor terminated the study early due to business reasons. As such, no data were collected for efficacy analyses.

    Time frame: Up to 18 Months

07

Results

Posted Jan 8, 2026
Limitations and caveats
This study was terminated for business reasons prior to completing enrollment. No efficacy data were collected and limited safety data were collected. No statistical comparisons between treatment arms could be made due to low subject numbers.

Participant flow

This study enrolled subjects from 11 February 2014 (first patient enrolled) through 02 September 2014 (Sponsor decision to end study). The study was terminated prior to completing enrollment due to Sponsor decision (not based on any safety results).

Participant flow — Overall Study
MilestoneArm 1 - Cabozantinib 40 mg, po QD + AbirateroneArm 2 - Cabozantinib 20 mg, po QD + AbirateroneArm 3 - Cabozantinib 20 mg, po QOD + AbirateroneArm 4 - Abiraterone Only
Started14131314
Completed0000
Not completed14131314
Withdrew: Sponsor decision to terminate study14121210
Withdrew: Progressive disease0111
Withdrew: Adverse event0001
Withdrew: Lack of efficacy0001
Withdrew: No treatment given0001

Outcome measures

PrimaryRadiographic Progression Free Survival (PFS)

PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause, as assessed by Independent Radiology Committee (IRC). The sponsor terminated the study early due to business reasons. As such, no data were collected for efficacy analyses.

Time frame:
Up to 18 Months

No measurements were reported for this outcome.

Adverse events

Collected over Up to 7 months. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 10/14 (0%)2/14 (14.3%)13/14 (92.9%)
Arm 21/14 (7.1%)4/14 (28.6%)10/14 (71.4%)
Arm 30/12 (0%)1/12 (8.3%)11/12 (91.7%)
Arm 41/13 (7.7%)1/13 (7.7%)11/13 (84.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventArm 1Arm 2Arm 3Arm 4
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/141/141/120/13
HypokalemiaMetabolism and nutrition disorders0/140/141/120/13
Atrial fibrillationCardiac disorders0/140/140/121/13
PneumoniaInfections and infestations0/140/140/121/13
Septic shockInfections and infestations0/140/140/121/13
AnemiaBlood and lymphatic system disorders1/140/140/120/13
Renal failure acuteRenal and urinary disorders1/140/140/120/13
Uncoded: left sided obstructive uropathyRenal and urinary disorders1/140/140/120/13
Myocardial infarctionCardiac disorders1/140/140/120/13
BronchitisInfections and infestations0/141/140/120/13
Most frequent other events
Showing 10 of 141
Most frequent other events
EventArm 1Arm 2Arm 3Arm 4
ArthralgiaMusculoskeletal and connective tissue disorders1/141/141/124/13
FatigueGeneral disorders4/143/142/123/13
Muscle spasmsMusculoskeletal and connective tissue disorders1/144/142/123/13
DysphoniaRespiratory, thoracic and mediastinal disorders4/141/140/121/13
HypertensionVascular disorders3/143/143/122/13
VomitingGastrointestinal disorders0/142/141/123/13
Blood alkaline phosphatase increasedInvestigations1/140/141/123/13
DizzinessNervous system disorders1/140/141/123/13
InsomniaPsychiatric disorders2/141/140/123/13
Aspartate aminotransferase increasedInvestigations3/140/140/120/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1 - Cabozantinib 40 mg, po QD + AbirateroneArm 2 - Cabozantinib 20 mg, po QD + AbirateroneArm 3 - Cabozantinib 20 mg, po QOD + AbirateroneArm 4 - Abiraterone OnlyTotal
<=18 years00000
Between 18 and 65 years223310
>=65 years1211101144
Age, Continuous
Age, Continuous(years)Arm 1 - Cabozantinib 40 mg, po QD + AbirateroneArm 2 - Cabozantinib 20 mg, po QD + AbirateroneArm 3 - Cabozantinib 20 mg, po QOD + AbirateroneArm 4 - Abiraterone OnlyTotal
Median76 (56 to 87)74 (61 to 83)73 (63 to 76)70 (55 to 84)73 (55 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 - Cabozantinib 40 mg, po QD + AbirateroneArm 2 - Cabozantinib 20 mg, po QD + AbirateroneArm 3 - Cabozantinib 20 mg, po QOD + AbirateroneArm 4 - Abiraterone OnlyTotal
Female00000
Male1413131454
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1 - Cabozantinib 40 mg, po QD + AbirateroneArm 2 - Cabozantinib 20 mg, po QD + AbirateroneArm 3 - Cabozantinib 20 mg, po QOD + AbirateroneArm 4 - Abiraterone OnlyTotal
Hispanic or Latino00000
Not Hispanic or Latino1312131452
Unknown or Not Reported11002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 - Cabozantinib 40 mg, po QD + AbirateroneArm 2 - Cabozantinib 20 mg, po QD + AbirateroneArm 3 - Cabozantinib 20 mg, po QOD + AbirateroneArm 4 - Abiraterone OnlyTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American03328
White1310101245
More than one race10001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Arm 1 - Cabozantinib 40 mg, po QD + AbirateroneArm 2 - Cabozantinib 20 mg, po QD + AbirateroneArm 3 - Cabozantinib 20 mg, po QOD + AbirateroneArm 4 - Abiraterone OnlyTotal
United States1413131454
08

Study locations

20 sites
  • Scottsdale, Arizona 85258, United States
  • Sedona, Arizona 86336, United States
  • Tucson, Arizona 85710, United States
  • Oxnard, California 93030, United States
  • San Diego, California 92108, United States
  • Aurora, Colorado 80012, United States
  • Aurora, Colorado 80045, United States
  • Athens, Georgia 30607, United States
  • Atlanta, Georgia 30318, United States
  • Peoria, Illinois 61615, United States
  • Wichita, Kansas 67214, United States
  • Las Vegas, Nevada 89148, United States
  • Raleigh, North Carolina 27607, United States
  • Tualatin, Oregon 97062, United States
  • Charleston, South Carolina 29414, United States
  • Greenville, South Carolina 29605, United States
  • Myrtle Beach, South Carolina 29572, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77024, United States
  • Salt Lake City, Utah 84112, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2026, 11 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2013
First posted
Nov 26, 2013
Start
Feb 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Jan 8, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01995058
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Feb 2014
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Jan 8, 2026
Last update
Jan 8, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion